Phase 1/1b Study of Lonafarnib and Temozolomide in Patients With Recurrent or Temozolomide Refractory Glioblastoma

BACKGROUND: Lonafarnib is an oral selective farnesyltransferase inhibitor, a class of drugs which have shown activity in preclinical glioma models. Temozolomide (TMZ) is an alkylating agent that is the first-line chemotherapy for glioblastoma. METHODS: The current study combined the cytotoxic agent...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Yust-Katz, Shlomit, Liu, Diane, Yuan, Ying, Liu, Vivien, Kang, Sanghee, Groves, Morris, Puduvalli, Vinay, Levin, Victor, Conrad, Charles, Colman, Howard, Hsu, Sigmonid, Alfred Yung, W. K., Gilbert, Mark R.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4001735/
https://ncbi.nlm.nih.gov/pubmed/23633392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28031
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars